OpenURL Connection Search

Select item for more details and to access through your institution.

A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma.
Published in:
European Journal of Haematology, 2004, v. 72, n. 1, p. 32, doi. 10.1046/j.0902-4441.2004.00177.x
By:
- Mileshkin, L.;
- Blum, R.;
- Seymour, J.F.;
- Patrikeos, A.;
- Hicks, R.J.;
- Prince, H.M.
Publication type:
Article
Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
Published in:
European Journal of Haematology, 2003, v. 71, n. 4, p. 250, doi. 10.1034/j.1600-0609.2003.00143.x
By:
- Kennedy, G.A.;
- Seymour, J.F.;
- Wolf, M.;
- Januszewicz, H.;
- Davison, J.;
- McCormack, C.;
- Ryan, G.;
- Prince, H.M.
Publication type:
Article
Severe respiratory syncytial virus pneumonia complicating fludarabine and cyclophosphamide treatment of chronic lymphocytic leukemia.
Published in:
European Journal of Haematology, 2002, v. 69, n. 1, p. 54, doi. 10.1034/j.1600-0609.2002.02745.x
By:
- Field, K.;
- Slavin, M.A.;
- Seymour, J.F.
Publication type:
Article
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Published in:
Leukemia (08876924), 2003, v. 17, n. 12, p. 2401, doi. 10.1038/sj.leu.2403158
By:
- Banford, S.;
- Rudzki, Z.;
- Harper, A.;
- Grigg, A.;
- Taylor, K.;
- Durrant, S.;
- Arthur, C.;
- Browett, P.;
- Schwarer, A.P.;
- Ma, D.;
- Seymour, J.F.;
- Bradstock, K.;
- Joske, D.;
- Lynch, K.;
- Gathmann, I.;
- Hughes, T.P.
Publication type:
Article
AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/ REFRACTORY CLL.
Published in:
Hematological Oncology, 2019, v. 37, p. 108, doi. 10.1002/hon.70_2629
By:
- Handunnetti, S.M.;
- Lew, T.E.;
- Lin, V.S.;
- Anderson, M.A.;
- Carney, D.;
- Wolf, M.;
- Came, N.;
- Juneja, S.;
- Westerman, D.;
- Tam, C.S.;
- Roberts, A.W.;
- Seymour, J.F.
Publication type:
Article
IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 106, doi. 10.1002/hon.69_2629
By:
- Wu, J.;
- Bolen, C.;
- Seymour, J.F.;
- Hillmen, P.;
- Eichhorst, B.;
- Eldering, E.;
- Kipps, T.J.;
- Langerak, A.W.;
- Mellink, C.;
- Kevie‐Kersemaekers, A.F.;
- Owen, C.;
- Chyla, B.;
- Punnoose, E.A.;
- Wang, J.;
- Boyer, M.;
- Humphrey, K.;
- Jiang, Y.;
- Kater, A.P.
Publication type:
Article
CLINICAL OUTCOMES FROM VENETOCLAX BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMAS.
Published in:
Hematological Oncology, 2019, v. 37, p. 535, doi. 10.1002/hon.221_2631
By:
- Lewis, K.L.;
- Dowling, M.;
- Bavishi, K.;
- Øvlisen, A.K.;
- Hamad, N.;
- Choi, P.;
- Grigg, A.;
- P'Ng, S.;
- Filshie, R.;
- Ritchie, D.S.;
- Bilmon, I.;
- Prince, H.M.;
- Wolf, M.;
- Hertzberg, M.;
- Chuah, H.;
- El‐Galaly, T.C.;
- Tam, C.S.;
- Seymour, J.F.;
- Cheah, C.Y.
Publication type:
Article
AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/ REFRACTORY CLL.
Published in:
Hematological Oncology, 2019, v. 37, p. 108, doi. 10.1002/hon.70_2629
By:
- Handunnetti, S.M.;
- Lew, T.E.;
- Lin, V.S.;
- Anderson, M.A.;
- Carney, D.;
- Wolf, M.;
- Came, N.;
- Juneja, S.;
- Westerman, D.;
- Tam, C.S.;
- Roberts, A.W.;
- Seymour, J.F.
Publication type:
Article
IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 106, doi. 10.1002/hon.69_2629
By:
- Wu, J.;
- Bolen, C.;
- Seymour, J.F.;
- Hillmen, P.;
- Eichhorst, B.;
- Eldering, E.;
- Kipps, T.J.;
- Langerak, A.W.;
- Mellink, C.;
- Kevie‐Kersemaekers, A.F.;
- Owen, C.;
- Chyla, B.;
- Punnoose, E.A.;
- Wang, J.;
- Boyer, M.;
- Humphrey, K.;
- Jiang, Y.;
- Kater, A.P.
Publication type:
Article
CLINICAL OUTCOMES FROM VENETOCLAX BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMAS.
Published in:
Hematological Oncology, 2019, v. 37, p. 535, doi. 10.1002/hon.221_2631
By:
- Lewis, K.L.;
- Dowling, M.;
- Bavishi, K.;
- Øvlisen, A.K.;
- Hamad, N.;
- Choi, P.;
- Grigg, A.;
- P'Ng, S.;
- Filshie, R.;
- Ritchie, D.S.;
- Bilmon, I.;
- Prince, H.M.;
- Wolf, M.;
- Hertzberg, M.;
- Chuah, H.;
- El‐Galaly, T.C.;
- Tam, C.S.;
- Seymour, J.F.;
- Cheah, C.Y.
Publication type:
Article
BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB-3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM).
Published in:
Hematological Oncology, 2017, v. 35, p. 70, doi. 10.1002/hon.2437_58
By:
- Trotman, J.;
- Opat, S.;
- Marlton, P.;
- Gottlieb, D.;
- Simpson, D.;
- Cull, G.;
- Ritchie, D.;
- Verner, E.;
- Ratnasingam, S.;
- Anderson, M.;
- Wood, P.;
- Wang, L.;
- Xue, L.;
- Hedrick, E.;
- Huang, J.;
- Hilger, J.;
- Seymour, J.F.;
- Roberts, A.W.;
- Tam, C.S.
Publication type:
Article
COMBINATION IBRUTINIB (IBR) AND VENETOCLAX (VEN) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): PRIMARY ENDPOINT ASSESSMENT OF THE PHASE 2 AIM STUDY.
Published in:
Hematological Oncology, 2017, v. 35, p. 144, doi. 10.1002/hon.2437_134
By:
- Tam, C.S.;
- Roberts, A.W.;
- Anderson, M.;
- Dawson, S.;
- Hicks, R.;
- Burbury, K.;
- Turner, G.;
- Di Iulio, J.;
- Bressel, M.;
- Westerman, D.;
- Agarwal, R.;
- Pott, C.;
- Dreyling, M.;
- Dawson, M.;
- Seymour, J.F.
Publication type:
Article
VENETOCLAX ( VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON- HODGKIN LYMPHOMA ( NHL).
Published in:
Hematological Oncology, 2017, v. 35, p. 203, doi. 10.1002/hon.2438_67
By:
- Davids, M.S.;
- Roberts, A.W.;
- Seymour, J.F.;
- Wierda, W.G.;
- Puvvada, S.D.;
- Gressick, L.;
- Alter, D.;
- Dunbar, M.;
- Zhou, L.;
- Kim, S.;
- Verdugo, M.;
- Gerecitano, J.F.
Publication type:
Article
CVP OR R-CVP GIVEN AFTER INVOLVED-FIELD RADIOTHERAPY IMPROVES PROGRESSION FREE SURVIVAL IN STAGE I-II FOLLICULAR LYMPHOMA: RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL.
Published in:
Hematological Oncology, 2017, v. 35, p. 31, doi. 10.1002/hon.2437_11
By:
- Macmanus, M.P.;
- Fisher, R.;
- Roos, D.;
- O'Brien, P.;
- Macann, A.;
- Tsang, R.;
- Davis, S.;
- Christie, D.;
- McClure, B.;
- Joseph, D.;
- Seymour, J.F.
Publication type:
Article
HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB-3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY.
Published in:
Hematological Oncology, 2017, v. 35, p. 234, doi. 10.1002/hon.2438_97
By:
- Seymour, J.F.;
- Opat, S.;
- Cull, G.;
- Trotman, J.;
- Gottlieb, D.;
- Simpson, D.;
- Marlton, P.;
- Anderson, M.;
- Ku, M.;
- Ritchie, D.S.;
- Ratnasingam, S.;
- Augustson, B.;
- Kim, W.;
- Wang, L.;
- Xue, L.;
- Hilger, J.;
- Huang, J.;
- Hedrick, E.;
- Roberts, A.W.;
- Tam, C.S.
Publication type:
Article
OUTCOMES WITH BRUTON TYROSINE KINASE INHIBITION IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA AFTER PROGRESSION ON VENETOCLAX.
Published in:
Hematological Oncology, 2017, v. 35, p. 236, doi. 10.1002/hon.2438_99
By:
- Anderson, M.;
- Lew, T.E.;
- Seymour, J.F.;
- Roberts, A.W.;
- Tam, C.
Publication type:
Article
Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies.
Published in:
American Journal of Hematology, 2004, v. 77, n. 1, p. 72, doi. 10.1002/ajh.20147
By:
- C.S. Tam;
- J. Galanos;
- J.F. Seymour;
- A.G. Pitman;
- R.J. Stark;
- H.M. Prince
Publication type:
Article
Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide – Response to mileshkin et al.
Published in:
2003
By:
- Mileshkin, Linda;
- Prince, H.M.;
- Seymour, J.F.;
- Biagi, J.J.
Publication type:
Letter

Found: 18